BeStock  

Bausch + Lomb Corp. BLCO

US equityMarket cap rank #1739Medical Instruments & Supplies
$19.38 −$1.31 (-6.33%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $19.40 +0.10%
Open$20.24
Prev close$20.69
Day range$19.30 – $20.50
Volume872.1K
Market cap$6.93B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$1.38B+7.3% YoY
Operating profit$185.00M+131.3% YoY
Net profit$35.00M+240.0% YoY
Diluted EPS$0.09+212.5% YoY
Free cash flow$178.00M+182.5% YoY
Operating cash flow$233.00M

Revenue, last 8 quarters

$1.3BDec '24$1.1BMar '25$1.3BJun '25$1.3BSep '25$1.4BDec '25$1.2BMar '26$1.4BJun '26$1.4BSep '26

Net profit, last 8 quarters

$-2.0MDec '24$-211.0MMar '25$-58.0MJun '25$-25.0MSep '25$-58.0MDec '25$-70.0MMar '26$-10.0MJun '26$35.0MSep '26

Diluted EPS by quarter

-0.01Dec '24-0.60Mar '25-0.18Jun '25-0.08Sep '25-0.16Dec '25-0.20Mar '26-0.04Jun '260.09Sep '26

Free cash flow by quarter

$-70.0MDec '24$-135.0MMar '25$-54.0MJun '25$63.0MSep '25$60.0MDec '25$-68.0MMar '26$82.0MJun '26$178.0MSep '26

Annual revenue

$3.4BFY20$3.8BFY21$3.8BFY22$4.1BFY23$4.8BFY24$5.1BFY25

Profitability & balance sheet

Gross margin62.6%
Operating margin9.4%
Net margin-2.0%
Return on equity-1.7%
Return on assets-0.8%
Return on invested capital1.0%
Current ratio1.56
Liabilities / assets53.4%
Cash & investments$513.00M
Total debt$5.10B
Net cash (debt)-$4.58B
Free cash flow / sales4.7%

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Vision Care$774.00M 56.3%
  • Pharmaceuticals$367.00M 26.7%
  • Surgical$234.00M 17.0%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $1.38B $1.39B $1.24B $5.10B $1.41B
Total Operating Revenue $1.38B $1.39B $1.24B $5.10B $1.41B
Cost of Revenue $486.00M $527.00M $483.00M $2.05B $533.00M
Gross Profit $889.00M $867.00M $761.00M $3.05B $872.00M
Operating Expense $704.00M $759.00M $702.00M $2.86B $714.00M
Selling and Admin Expenses $556.00M $588.00M $544.00M $2.23B $564.00M
Research & Development $91.00M $114.00M $101.00M $371.00M $94.00M
Depreciation & Amortization & Depletion $57.00M $57.00M $57.00M $258.00M $56.00M
-Depreciation & Amortization $57.00M $57.00M $57.00M $258.00M $56.00M
Operating Profit $185.00M $108.00M $59.00M $188.00M $158.00M
Net Non-Operating Interest Income (Expense) -$93.00M -$89.00M -$93.00M -$409.00M -$95.00M
Non-Operating Interest Income $2.00M $4.00M $4.00M $12.00M $3.00M
Non-Operating Interest Expense $95.00M $93.00M $97.00M $421.00M $98.00M
Other Income (Expense) -$34.00M -$30.00M -$30.00M -$96.00M -$50.00M
Gain on Sale of Security -$4.00M -$5.00M -$3.00M -$15.00M -$4.00M
Special Income (Charges) -$30.00M -$20.00M -$27.00M -$81.00M -$46.00M
-Less:Restructuring and Mergern & Acquisition $18.00M $6.00M $11.00M $38.00M $40.00M
-Less:Impairment of Capital Assets $4.00M – – $0.00 $0.00
-Less:Other Special Charges $8.00M $5.00M $19.00M $49.00M $6.00M
-Gain on Sale of Property/Plant/Equipment $0.00 $0.00 $3.00M $6.00M $0.00
Pretax Profit $58.00M -$11.00M -$64.00M -$317.00M $13.00M
Tax $23.00M -$1.00M $6.00M $35.00M $71.00M
Net Profit $35.00M -$10.00M -$70.00M -$352.00M -$58.00M
Profit from Continuing Operations $35.00M -$10.00M -$70.00M -$352.00M -$58.00M
Minority Interests $3.00M $4.00M $1.00M $8.00M $0.00
Net Income to Parent Company $32.00M -$14.00M -$71.00M -$360.00M -$58.00M
Net Income to Common Stockholders $32.00M -$14.00M -$71.00M -$360.00M -$58.00M
Basic EPS $0.09 -$0.04 -$0.20 -$1.02 -$0.16
Diluted EPS $0.09 -$0.04 -$0.20 -$1.02 -$0.16
-Less:Write Off – $9.00M – – –
Other Non-Operating Income (Expenses) – -$5.00M – – –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $13.96B $13.86B $13.78B $14.02B $14.02B
Total Current Assets $3.06B $2.92B $2.78B $2.98B $2.98B
Cash and Cash Equivalents & Short-Term Investments $513.00M $367.00M $268.00M $383.00M $383.00M
-Cash and Cash Equivalents $513.00M $367.00M $268.00M $383.00M $383.00M
Receivables $1.15B $1.16B $1.11B $1.22B $1.22B
-Accounts Receivable $1.15B $1.16B $1.11B $1.22B $1.22B
Inventory $1.01B $999.00M $977.00M $976.00M $976.00M
Restricted Cash $2.00M $11.00M $11.00M $14.00M $14.00M
Other Current Assets $386.00M $385.00M $414.00M $383.00M $383.00M
Total Non-Current Assets $10.90B $10.94B $11.00B $11.05B $11.05B
Net PPE $1.81B $1.80B $1.79B $1.76B $1.76B
Goodwill and Other Intangible Assets $7.85B $7.89B $7.96B $8.04B $8.04B
-Goodwill $4.71B $4.72B $4.74B $4.76B $4.76B
-Other Intangible Assets $3.13B $3.17B $3.23B $3.28B $3.28B
Non-Current Deferred Assets $963.00M $952.00M $945.00M $934.00M $934.00M
Other Non-Current Assets $284.00M $294.00M $302.00M $310.00M $310.00M
Total Liabilities $7.45B $7.42B $7.33B $7.50B $7.50B
Total Current Liabilities $1.96B $1.89B $1.82B $1.92B $1.92B
Payables $367.00M $426.00M $407.00M $388.00M $388.00M
-Accounts Payable $367.00M $426.00M $407.00M $388.00M $388.00M
Current Accrued Expenses $693.00M $632.00M $603.00M $756.00M $756.00M
Short-Term Debt and Capital Lease Obligation $45.00M $43.00M $39.00M $39.00M $39.00M
-Current Debt $45.00M $43.00M $39.00M $39.00M $39.00M
Other Current Liabilities $590.00M $537.00M $560.00M $487.00M $487.00M
Total Non-Current Liabilities $5.49B $5.53B $5.51B $5.58B $5.58B
Long Term Debt and Capital Lease Obligation $5.05B $5.07B $5.03B $5.04B $5.04B
-Long Term Debt $5.05B $5.07B $5.03B $5.04B $5.04B
Non-Current Deferred Liabilities $19.00M $18.00M $19.00M $19.00M $19.00M
Other Non-Current Liabilities $420.00M $435.00M $458.00M $521.00M $521.00M
Total Equity $6.51B $6.44B $6.45B $6.52B $6.52B
Stockholders' Equity $6.44B $6.38B $6.38B $6.45B $6.45B
Capital Stock $0.00 $0.00 $0.00 $0.00 $0.00
-Common Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $8.65B $8.61B $8.58B $8.56B $8.56B
Retained Earnings -$984.00M -$1.02B -$1.00B -$931.00M -$931.00M
Gains/Losses Not Affecting Retained Earnings -$1.22B -$1.22B -$1.20B -$1.18B -$1.18B
Minority Interests $71.00M $68.00M $73.00M $71.00M $71.00M
-Gross PPE – – – $3.66B $3.66B
-Accumulated Depreciation – – – -$1.90B -$1.90B

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $233.00M $153.00M $32.00M $283.00M $136.00M
Net cash flow from continuing operations $233.00M $153.00M $32.00M $283.00M $136.00M
Net Income from Continuing Operations $35.00M -$10.00M -$70.00M -$352.00M -$58.00M
Gain/Loss from Continuing Operations $6.00M $3.00M $1.00M -$8.00M $0.00
Depreciation & Depletion & Amortization $102.00M $102.00M $101.00M $421.00M $99.00M
Deferred Tax -$3.00M -$21.00M -$12.00M -$32.00M $64.00M
Other Non-Cash Items $14.00M $3.00M $10.00M $56.00M $26.00M
Change in Working Capital $37.00M $19.00M -$46.00M $18.00M -$67.00M
-Change in Receivables $9.00M -$53.00M $108.00M -$148.00M -$130.00M
-Change in Inventory -$7.00M -$36.00M -$22.00M $38.00M $28.00M
-Change in Prepaid Assets -$25.00M $13.00M -$38.00M $20.00M $37.00M
-Change in Payables and Accrued Expense $60.00M $95.00M -$94.00M $108.00M -$2.00M
Net cash flow from investing -$73.00M -$87.00M -$130.00M -$455.00M -$188.00M
Net Cash Flow from Continuing Investing Activities -$73.00M -$87.00M -$130.00M -$455.00M -$188.00M
Net PPE Purchase and Sale -$55.00M -$71.00M -$100.00M -$349.00M -$76.00M
Net Business Purchase and Sale -$23.00M -$15.00M -$38.00M -$122.00M -$109.00M
Net Investment Purchase and Sale $1.00M -$1.00M $0.00 -$3.00M -$3.00M
Net Other Investing Changes $0.00 $0.00 $3.00M $7.00M $0.00
Financing Cash Flow -$22.00M $34.00M -$20.00M $225.00M $116.00M
Net Cash Flow from Continuing Financing Activities -$22.00M $34.00M -$20.00M $225.00M $116.00M
Net Issuance Payments Of Debt -$17.00M $49.00M -$3.00M $261.00M $117.00M
Proceeds from Stock Option Exercised $0.00 $0.00 $2.00M – –
Net Other Financing Charges -$5.00M -$15.00M -$19.00M -$36.00M -$1.00M
Ending Cash Balance $515.00M $378.00M $279.00M $397.00M $397.00M
Net Change in Cash $138.00M $100.00M -$118.00M $53.00M $64.00M
Beginning Cash Balance $378.00M $279.00M $397.00M $316.00M $332.00M
Effect of Exchange Rate Changes -$1.00M -$1.00M $0.00 $28.00M $1.00M
Free Cash Flow $178.00M $82.00M -$68.00M -$66.00M $60.00M

Discussion

No comments yet — be the first to weigh in on BLCO.

Sign in to join the discussion.

Scroll to Top